Idexx Laboratories (IDXX) Stock
Leading provider of veterinary and water diagnostic tests. Here's the price, business snapshot, and what's worth knowing about Idexx Laboratories in August 2026.
IDEXX Laboratories is a leading provider of diagnostic tests, instruments and software for the animal health and water testing markets. The company sells a mix of instruments and high-margin consumables as well as practice-management and diagnostic software that together create recurring revenue streams and close customer relationships with veterinary clinics and laboratories. IDEXX benefits from structural trends such as rising pet ownership and increased spending on companion animal care, while also operating in water and livestock testing markets. Investors should note it is exposed to competitive pressures, regulatory requirements and technological change, and its performance can vary with regional veterinary spending and currency moves. The company’s market cap (around $51 billion) reflects sizeable scale and long-term growth expectations, but this is general information only and not personal financial advice — suitability depends on your goals, risk tolerance and timeframe.
Why It’s Moving
IDEXX is moving on stronger-than-expected results, higher guidance, and steady demand for pet diagnostics.
- IDEXX reported second-quarter revenue of $1.22 billion, up 10% year over year, showing that demand for pet diagnostics is still growing despite softer veterinary clinic traffic.
- Adjusted earnings came in ahead of expectations, and management lifted full-year guidance, which helped reinforce confidence in the company’s ability to keep expanding margins.
- Investor attention also shifted to product momentum, including continued adoption of newer diagnostic platforms that support recurring test usage and deeper penetration in clinics.
IDEXX is moving on stronger-than-expected results, higher guidance, and steady demand for pet diagnostics.
- IDEXX reported second-quarter revenue of $1.22 billion, up 10% year over year, showing that demand for pet diagnostics is still growing despite softer veterinary clinic traffic.
- Adjusted earnings came in ahead of expectations, and management lifted full-year guidance, which helped reinforce confidence in the company’s ability to keep expanding margins.
- Investor attention also shifted to product momentum, including continued adoption of newer diagnostic platforms that support recurring test usage and deeper penetration in clinics.
Sixth Month Growth Performance
When is the next earnings date for IDEXX LABORATORIES INC (IDXX)?
The next earnings date for IDXX is expected on November 2, 2026. This report will cover Q3 2026 results, following the company’s typical early-November earnings pattern. If the company has not formally confirmed the date yet, that timing remains the best current estimate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IDEXX Laboratories' stock with a target price of $771.46, showing growth potential.
Financial Health
IDEXX Laboratories is generating strong revenue and cash flow, indicating good financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Steady Consumables Demand
High-margin consumables and recurring test volumes can support predictable revenue, though demand may fluctuate with vet clinic activity.
Global Pet Care Trends
Growing pet ownership and higher veterinary spending provide long-term tailwinds, while international expansion adds opportunity and exposure to currency risk.
Innovation & Software
Diagnostics instruments and practice-management software help differentiate the offering, yet product cycles and competition create execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
